- Home
- RLAY vs BCYC Comparison
RLAY vs BCYC Comparison
Compare RLAY & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- BCYC
- Stock Information
- Founded
- RLAY 2015
- BCYC 2009
- Country
- RLAY United States
- BCYC United Kingdom
- Employees
- RLAY N/A
- BCYC N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- BCYC Health Care
- Exchange
- RLAY Nasdaq
- BCYC Nasdaq
- Market Cap
- RLAY 811.8M
- BCYC 896.2M
- IPO Year
- RLAY 2020
- BCYC 2019
- Fundamental
- Price
- RLAY $3.92
- BCYC $11.66
- Analyst Decision
- RLAY Strong Buy
- BCYC Buy
- Analyst Count
- RLAY 10
- BCYC 9
- Target Price
- RLAY $20.11
- BCYC $33.25
- AVG Volume (30 Days)
- RLAY 1.4M
- BCYC 275.5K
- Earning Date
- RLAY 02-28-2025
- BCYC 02-25-2025
- Dividend Yield
- RLAY N/A
- BCYC N/A
- EPS Growth
- RLAY N/A
- BCYC N/A
- EPS
- RLAY N/A
- BCYC N/A
- Revenue
- RLAY $10,006,000.00
- BCYC $36,898,000.00
- Revenue This Year
- RLAY N/A
- BCYC $41.07
- Revenue Next Year
- RLAY N/A
- BCYC N/A
- P/E Ratio
- RLAY N/A
- BCYC N/A
- Revenue Growth
- RLAY N/A
- BCYC 48.60
- 52 Week Low
- RLAY $3.50
- BCYC $11.14
- 52 Week High
- RLAY $10.89
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- RLAY 41.60
- BCYC 34.58
- Support Level
- RLAY $3.85
- BCYC $11.14
- Resistance Level
- RLAY $4.19
- BCYC $13.11
- Average True Range (ATR)
- RLAY 0.28
- BCYC 0.69
- MACD
- RLAY -0.02
- BCYC 0.08
- Stochastic Oscillator
- RLAY 24.80
- BCYC 22.32
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.